Fitia vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI nutrition and meal planning app with 10M+ users across Latin America; personalized diet plans and calorie tracking competing with MyFitnessPal for Spanish-speaking health consumers.
About
Fitia is a mobile nutrition and diet app powered by AI-driven meal planning — providing personalized diet plans, automated calorie and macro tracking, food database scanning, and weight loss guidance tailored to each user's goals, body metrics, and food preferences. Founded in 2018 in Lima, Peru by Renato Salas, Fitia is Y Combinator-backed and raised $125,000 from YC alongside Goodwater Capital and HOF Capital, growing to over 10 million users across Latin America and generating $3.5 million in revenue in 2024.\n\nFitia's app builds personalized weekly meal plans based on user-specified goals (weight loss, muscle gain, maintenance), dietary restrictions (vegetarian, gluten-free, lactose intolerance), and food preferences — then automatically calculates the daily calorie and macronutrient targets. Users log meals by searching the app's food database (extensive Latin American and international food coverage), scanning barcodes, or taking photos for AI-powered food recognition. The app's market positioning focuses on making professional-quality nutrition guidance accessible at low cost, serving a demographic that can't afford dietitian consultations.\n\nIn 2025, Fitia competes in the nutrition tracking and diet app market with MyFitnessPal (the dominant calorie tracking app globally), Cronometer, Noom, and regional diet apps for Latin American nutrition and weight management. Latin America represents a large underserved market for digital health apps given the region's rapidly growing smartphone penetration and rising obesity rates driving health consciousness. Fitia's Spanish and Portuguese language capabilities and Latin American food database give it advantages over global competitors in the region. The 2025 strategy focuses on growing the premium subscription conversion rate, expanding to additional Latin American markets, and adding AI-powered coaching features that increase engagement and retention beyond passive calorie tracking.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.